Table 2.
Secondary outcomes, categorical variables
| Number of participants/total with data available (n/N) | Prevalence (%) | Effect (95% CI) | |
|---|---|---|---|
| Anaemia at day 84 (haemoglobin <110 g/L) | |||
| Reference group | 63/139 | 45% | ·· |
| 60 mg screen-and-treat approach | 75/131 | 57% | 11·9 (0·1 to 23·8) |
| 30 mg screen-and-treat approach | 86/145 | 59% | 14·0 (2·5 to 25·5) |
| Ready-and-safe to receive iron at day 84 (hepcidin <2·5 μg/L) | |||
| Reference group | 30/140 | 21% | ·· |
| 60 mg screen-and-treat approach | 55/132 | 42% | 20·2 (9·4 to 31·1) |
| 30 mg screen-and-treat approach | 77/147 | 52% | 31·0 (20·4 to 41·5) |
| Ferritin index >2·0 at day 84 | |||
| Reference group | 82/140 | 59% | ·· |
| 60 mg screen-and-treat approach | 116/133 | 87% | 28·6 (18·7 to 38·6) |
| 30 mg screen-and-treat approach | 131/147 | 89% | 30·5 (21·0 to 40·1) |
| Iron-deficiency anaemia at day 84 | |||
| Reference group | 24/140 | 17% | ·· |
| 60 mg screen-and-treat approach | 38/131 | 29% | 11·9 (1·9 to 21·8) |
| 30 mg screen-and-treat approach | 58/146 | 40% | 22·6 (12·5 to 32·7) |
| Iron dosage (% of weeks in which iron was received) | |||
| Reference group | 1974/1974* | 100% | ·· |
| 60 mg screen-and-treat approach | 1025/1905* | 46% | –53·8 (–56·0 to −51·6) |
| 30 mg screen-and-treat approach | 952/2009* | 53% | –47·4 (–49·6 to −45·2) |
| Adherence | |||
| Reference group | 275/1974* | 86% | ·· |
| 60 mg screen-and-treat approach | 260/1905* | 86% | 0·3 (0·3 to 0·3) |
| 30 mg screen-and-treat approach | 246/2009* | 86% | 1·7 (1·7 to 1·7) |
*
Data are cases/person-weeks.